Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 10, 2006

First Fully Human Anti-IL6 Antibody Under Development

  • Vaccinex granted OPi exclusive worldwide rights to its fully human anti-interleukin-6 (IL-6) antibody, OPR-003, and to several alternate antibodies, according to an agreement between the two companies. OPR-003 is the first fully human antibody to be developed within the anti-IL6 and anti-IL6R class, according to Vaccinex.

    In 2004, OPi and Vaccinex initiated a research collaboration to discover fully human antibodies derived from OPi’s murine anti-IL6 antibody, elsilimomab, which showed positive proof-of-concept clinical data in malignant hematological diseases. The collaboration identified a panel of high affinity fully-human anti-IL6 antibodies with comparable functionality to elsilimomab, says Vaccinex. OPi has initiated preclinical development.

    “Given its clinical potential and its competitive advantages, advancing these fully human antibodies to the clinic will be one of our key objectives,” says Gilles Alberici, Ph.D., president and founder of OPi.

    According to the agreement, Vaccinex will be eligible to receive milestone payments and royalties and will have the opportunity to participate as a co-development partner in certain markets.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »